Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company’s stock, valued at $342,303. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Neumora Therapeutics Trading Down 2.8 %

Shares of NASDAQ NMRA traded down $0.47 during midday trading on Friday, hitting $16.49. The company’s stock had a trading volume of 1,916,200 shares, compared to its average volume of 676,344. The business’s 50 day moving average is $12.62 and its two-hundred day moving average is $11.34. Neumora Therapeutics, Inc. has a 12-month low of $8.33 and a 12-month high of $21.00. The firm has a market cap of $2.63 billion and a P/E ratio of -6.64.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). On average, analysts predict that Neumora Therapeutics, Inc. will post -1.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on NMRA shares. Mizuho started coverage on Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 price objective for the company. HC Wainwright began coverage on Neumora Therapeutics in a research note on Tuesday, October 1st. They issued a “buy” rating and a $30.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a report on Friday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.83.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD purchased a new position in Neumora Therapeutics during the 1st quarter worth $10,354,000. Callan Capital LLC grew its stake in Neumora Therapeutics by 222.6% during the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after purchasing an additional 456,207 shares during the last quarter. Rhumbline Advisers grew its stake in Neumora Therapeutics by 488.3% during the 2nd quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock valued at $1,015,000 after purchasing an additional 85,706 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Neumora Therapeutics by 79.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company’s stock valued at $1,099,000 after purchasing an additional 49,527 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at about $566,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.